The FDA has approved Linzess (linaclotide) for children aged 7 and older with IBS-C, marking the first FDA-approved drug for ...
Rifaximin is as effective as the low-FODMAP diet in managing irritable bowel syndrome and offers quicker symptom relief and ...
The FDA expands use of linaclotide to children as young as age 7 years with irritable bowel syndrome with constipation (IBS-C ...
The US medicines regulator has approved Linzess (linaclotide) capsules for children aged seven years and older with irritable ...
The FDA has updated the label indication for linaclotide capsules for the treatment of irritable bowel syndrome with ...
The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...
B. Longum is known as a “good bacteria” that helps break down food and absorb nutrients, which can help ease digestive ...
The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of irritable bowel syndrome with constipation (IBS-C) in patients 7 years of age and older. Previously, ...
FDA approves IBS drug for children, Linzess, to treat pediatric IBS-C in patients ages 7 and older with proven safety and efficacy.
Long-term, low doses of THC mitigate many harmful side effects and inflammation caused by HIV and antiretroviral therapy (ART ...
The FDA has approved linaclotide (Linzess) capsules for pediatric patients 7 years and older with irritable bowel syndrome with constipation, according to a Nov. 5 news release. Linzess is the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback